Cabaletta Bio, Inc. — Q1 2023 Form 10-Q Summary
Business context and reporting period
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T-cell therapies for autoimmune diseases through its CABA platform, including CARTA and CAART strategies. The filing covers the three months ended March 31, 2023, and was filed May 11, 2023. The company has no approved products and has generated no product revenue.
Financial condition and key metrics
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $12.4 million | $9.2 million | +$3.3 million |
| General and administrative expense | $4.5 million | $3.8 million | +$0.7 million |
| Total operating expenses | $17.0 million | $13.0 million | +$4.0 million |
| Interest income | $1.1 million | $0.1 million | +$1.0 million |
| Net loss | $15.9 million | $12.9 million | Loss increased $2.9 million |
| Net loss per share | $0.45 | $0.45 | No change |
| Cash used in operating activities | $12.6 million | $12.8 million | Improved $0.2 million |
Gross and operating margins are not meaningful because the company has no revenue. Accumulated deficit was $181.4 million at March 31, 2023. Cash and cash equivalents were $93.8 million, compared with $81.6 million at December 31, 2022; the increase primarily reflected $25.0 million of investment maturities, partially offset by operating cash usage.
The company had no credit facility or committed sources of capital and disclosed no conventional debt. Operating lease liabilities totaled $4.7 million, including $2.2 million due within one year. Total assets were $103.4 million and stockholders’ equity was $91.7 million at March 31, 2023.
Material changes versus the prior comparable period
- Research and development expense increased 36%, driven primarily by $2.3 million of intellectual-property license costs, higher development services, and increased personnel costs.
- Q1 intellectual-property costs included a $1.2 million upfront fee under the Autolus agreement and a $1.0 million milestone payable to IASO upon clearance of the CABA-201 IND.
- Sponsored research expense declined $1.1 million as certain CAART research agreements were completed in 2022; clinical-trial costs declined $0.2 million due to timing.
- Stock-based compensation increased to $2.5 million from $1.8 million.
- Interest income increased substantially because of higher interest rates and cash balances.
- Cash flow from investing activities changed from a $49.9 million use in Q1 2022, primarily for investment purchases, to $24.6 million provided in Q1 2023 from investment maturities.
- Common shares outstanding increased to 31.3 million at March 31, 2023 from 29.4 million at December 31, 2022, primarily reflecting exercise of pre-funded warrants.
Guidance, outlook, commentary, risks and unusual items
Management expects substantial operating losses and increasing research, development, manufacturing and general and administrative expenses for the foreseeable future. The company stated that March 31 cash and cash equivalents should fund projected operations for at least 12 months after filing, while its current operating plan indicates funding into the first quarter of 2025. These estimates depend on assumptions that may prove incorrect, and additional financing will be required.
- The CABA-201 IND was cleared in March 2023. The company planned to initiate a Phase 1/2 trial in SLE and lupus nephritis later in 2023, with three-month clinical data anticipated in the first half of 2024.
- In April 2023, CABA-201 received FDA Fast Track Designation for SLE and lupus nephritis.
- DSG3-CAART remains in the DesCAARTes trial. The company prioritized a combination cohort using IVIG and cyclophosphamide after limited evidence of activity and persistence in earlier monotherapy cohorts.
- MuSK-CAART remains in the MusCAARTes trial. Six-month combination-cohort clinical data for DSG3-CAART and MuSK-CAART were anticipated in the first half of 2024.
- Key execution risks include patient enrollment, clinical safety and efficacy, cytokine release syndrome and neurotoxicity, potential B-cell aplasia or hypogammaglobulinemia with CABA-201, manufacturing complexity, supply of lentiviral vectors, technology transfer, and reliance on Penn, WuXi and other third parties.
- The company remains highly dependent on licenses from Penn, CHOP and IASO. IASO may receive up to $162 million in total milestone consideration, plus royalties, if specified development and sales milestones are achieved.
- In May 2023, the company amended its Oxford Biomedica license and supply agreement to include CABA-201 for a $0.5 million upfront fee.
- The company filed a new $100 million shelf-supported ATM program, effective April 26, 2023; no shares had been sold under the program as of the filing. It terminated its prior 2020 ATM agreement on May 10, 2023 without a termination penalty.
- The company reported minimal exposure to the Silicon Valley Bank closure and no material adverse impact on liquidity or operations. It reported no material litigation as of March 31, 2023 and effective disclosure controls.
Most important facts for investors to verify
- Whether the stated cash runway into Q1 2025 remains valid after clinical-trial, manufacturing and licensing expenditures.
- Actual enrollment, safety, persistence and efficacy data from the DesCAARTes and MusCAARTes trials.
- Timing, enrollment and early clinical results for the CABA-201 Phase 1/2 trial.
- Availability and scalability of manufacturing capacity at Penn, WuXi, Oxford and other suppliers, including lentiviral-vector supply.
- Future financing needs, potential dilution under the $100 million ATM program, and the remaining balance of pre-funded warrants and equity awards.
- Potential milestone, royalty and sublicense obligations under the IASO, Penn, Autolus, Artisan and Oxford agreements.
- Whether emerging safety, regulatory or clinical developments could delay or prevent approval of any product candidate.